Coronavirus vaccine trials: While China has four vaccine candidates in third or final stages of clinical trials, there are at least two companies from the United States and one from UK and Germany, which are planning to rollout vaccine before December, if everything goes as per the plan

Gold, Silver prices today:  On the Multi Commodity Exchange, Gold October Futures gained Rs 166 at Rs 51,935, after hitting an intraday high of Rs 51,943 against the previous close of Rs 51,769 per 10 gm.

China launched a vaccine emergency use programme in July, offering three experimental shots developed by a unit of state pharmaceutical giant China National Pharmaceutical Group (Sinopharm) and U.S.-listed Sinovac Biotech

Forex traders said news related to coronavirus vaccine and sustained foreign fund inflows also aided to gains in the local unit

Gold, Silver prices today: Commodity analysts said traders are awaiting the outcome from the US central bank's two-day policy meeting, scheduled on September 15-16.

A unit of state pharmaceutical giant China National Pharmaceutical Group (Sinopharm) and U.S.-listed Sinovac Biotech are developing the three vaccines under the state's emergency use programme

India Stock Market Highlights Today: Titan, followed by Sun Pharma, HDFC, ICICI Bank, Bajaj Finance, NTPC, HDFC Bank and M&M were among the major gainers on Sensex pack today. On the other hand, Tech Mahindra, HCL Tech, Kotak Bank, ITC and Bharti Airtel were among the laggards

A Chinese virologist currently based out of Hong Kong has claimed that the new coronavirus was created in a lab in Wuhan

Claiming to be Ultimate game-changers, Toshiba 4K televisions feature Dolby Vision with Full-array 4K Ultra HD resolution

Another leading candidate for coronavirus vaccine is Moderna. The company said that it is talking to multiple countries for the rollout of the COVID-19 vaccine.

Benchmark equity indices - Sensex and Nifty - closed in red on Wednesday on global sell-off, border tensions with China and concerns around coronavirus vaccine

The CP therapy involves taking antibodies from the blood of a person who has recovered from COVID-19 and transfusing those into an active coronavirus patient to help kickstart the immune system to fight the infection

Dr VK Paul informed the Russian government has approached India to facilitate the Phase-3 trial of their vaccine and also manufacture Sputnik V through Indian companies

Health officials have been concerned about whether experimental vaccines could safely protect the elderly, whose immune systems usually react less robustly to vaccines, against the virus that has led to nearly 890,000 deaths worldwide

Russia's medical watchdog Roszdravnadzor will soon assess vaccine for quality check and could get approval by September 13, following which government will authorise vaccine for civilian use

The extent of inoculations under the emergency program, which China launched in July but has released few details about, points to how actively it is using experimental vaccines in the hopes of protecting essential workers against a potential COVID-19 resurgence

Russia's COVID-19 vaccine safe, produces immune response: LancetRussia's potential coronavirus vaccine, Sputnik V, approved in the country last month, induced an antibody response in all participants with no serious side effects, according to the first peer-reviewed data on studies of the project. The vaccine produced a response in T-cells, a type of white blood cells that helps the immune system combat any infection, according to the preliminary results from phase 1 and phase 2 trials as pu...

COVID-19 vaccine update: In this study, experts reported on two trials which took place in Russian hospitals involving 76 healthy adults in the age bracket 18-60 years, who were given a two-part immunisation

COVAX is co-led by GAVI, the WHO and the Coalition for Epidemic Preparedness Innovations (CEPI), and is designed to discourage national governments from hoarding COVID-19 vaccines and to focus on first vaccinating the most high-risk people in every country

Michael Osterholm, a University of Minnesota infectious disease expert, said he was concerned about an \"October surprise\" with a vaccine being rushed through ahead of the election